Discovery of Marburg virus neutralizing antibodies from virus-naïve human antibody repertoires using large-scale structural predictions
Abstract
Marburg virus (MARV) is a member of the Filoviridae family that causes severe hemorrhagic fevers with high fatality rates in humans. Despite the major efforts made to develop an effective vaccine after the most recent filovirus outbreak, still no Food and Drug Administration-licensed MARV disease vaccines exist. A good vaccine should be capable of eliciting neutralizing antibodies in MARV-naïve humans. This requires preexistence of antibodies with some affinity to the antigen. Here we used a large-scale computational antibody structure prediction approach to identify whether the epitope of the human anti-MARV monoclonal antibody MR78 can be recognized by antibodies from MARV-naïve humans and thus whether it is a promising candidate for vaccine design.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 23, 2020
- Source ID
- 10.1073/pnas.1922654117
Entities
People
- Alexander Bukreyev
- Alexander M Sevy
- Amandeep K. Sangha
- Andrew Trivette
- James E. Crowe, Jr.
- Jens Meiler
- Joseph X. Reidy
- Kai Huang
- Nina Bozhanova
- Pavlo Gilchuk
- Rachel S. Nargi
- Robert H. Carnahan
Organizations
- Defense Threat Reduction Agency
- Leipzig University
- National Center for Advancing Translational Sciences
- National Center for Research Resources
- National Institutes of Health
- University of Texas Medical Branch
- Vanderbilt University
- Vanderbilt University Medical Center